Press Releases Choose Year All Items 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Search Press Releases Found 211 Results November 2, 2022 Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022 October 17, 2022 Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia September 9, 2022 Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market August 22, 2022 Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia August 9, 2022 Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates May 4, 2022 Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates April 7, 2022 Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia March 1, 2022 Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates February 28, 2022 Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin November 8, 2021 Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates «...23456...1020...»